Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402255 | 0.87 | MAPT (0.38) | SIGMAR1 | |
| SCHEMBL6728925 | 0.86 | SIGMAR1 (0.51) | SIGMAR1ALDH1A1LMNAPOLBGAA | |
| SCHEMBL7271114 | 0.81 | FAAH (0.47) | MEN1KMT2A | |
| SCHEMBL1875799 | 0.81 | LTA4H (0.38) | SIGMAR1ALDH1A1 | |
| SCHEMBL1005039 | 0.81 | LTA4H (0.38) | SIGMAR1ALDH1A1 | |
| SCHEMBL1005038 | 0.81 | LTA4H (0.38) | SIGMAR1ALDH1A1 | |
| SCHEMBL64954 | 0.80 | SIGMAR1 (0.64) | SIGMAR1ALDH1A1LMNAPOLBGAA | |
| SCHEMBL4110162 | 0.80 | CCR3 (0.48) | SIGMAR1 | |
| SCHEMBL16432830 | 0.79 | THRB (0.43) | ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL16432829 | 0.79 | THRB (0.43) | ALDH1A1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1784410-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2009-07-15 | — | — | EP | disclosed |
| US-20070161627-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
| EP-1784410-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006020561-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161627-A1 | Antibacterial agents | NQO2, NQO1, NDUFV2 | SIGMAR1 957/4885ALDH1A1 2730/4885LMNA 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.